Macquarie Group LTD Alnylam Pharmaceuticals, Inc. Transaction History

Macquarie Group LTD

  • $90.3 Billion
  • Q3 2024

A detailed history of Macquarie Group LTD transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 72,616 shares of ALNY stock, worth $18.4 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
72,616
Previous 59,455 22.14%
Holding current value
$18.4 Million
Previous $14.4 Million 38.26%
% of portfolio
0.02%
Previous 0.02%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$233.81 - $287.01 $3.08 Million - $3.78 Million
13,161 Added 22.14%
72,616 $20 Million
Q2 2024

Aug 09, 2024
BUY
$143.31 - $247.0 $508,463 - $876,356
3,548 Added 6.35%
59,455 $14.4 Million
Q1 2024

May 14, 2024
BUY
$146.51 - $198.2 $1.3 Million - $1.76 Million
8,890 Added 18.91%
55,907 $8.36 Million
Q4 2023

Feb 14, 2024
BUY
$151.41 - $196.57 $168,216 - $218,389
1,111 Added 2.42%
47,017 $9 Million
Q3 2023

Nov 14, 2023
BUY
$170.77 - $211.65 $150,619 - $186,675
882 Added 1.96%
45,906 $8.13 Million
Q2 2023

Aug 14, 2023
SELL
$185.01 - $212.05 $130,432 - $149,495
-705 Reduced 1.54%
45,024 $8.55 Million
Q1 2023

May 15, 2023
BUY
$182.66 - $235.53 $93,339 - $120,355
511 Added 1.13%
45,729 $9.16 Million
Q4 2022

Feb 21, 2023
BUY
$185.53 - $241.31 $173,285 - $225,383
934 Added 2.11%
45,218 $10.7 Million
Q3 2022

Nov 14, 2022
BUY
$138.54 - $232.0 $187,306 - $313,664
1,352 Added 3.15%
44,284 $8.86 Million
Q2 2022

Aug 15, 2022
SELL
$120.42 - $169.29 $33,597 - $47,231
-279 Reduced 0.65%
42,932 $6.26 Million
Q1 2022

May 16, 2022
BUY
$127.18 - $173.91 $12,209 - $16,695
96 Added 0.22%
43,211 $7.06 Million
Q4 2021

Feb 11, 2022
SELL
$159.56 - $209.29 $1.67 Million - $2.19 Million
-10,478 Reduced 19.55%
43,115 $7.31 Million
Q2 2021

Aug 13, 2021
BUY
$128.63 - $176.89 $12,863 - $17,689
100 Added 0.19%
53,593 $9.09 Million
Q1 2021

May 14, 2021
BUY
$126.83 - $175.69 $1.29 Million - $1.79 Million
10,198 Added 23.55%
53,493 $7.55 Million
Q4 2020

Feb 16, 2021
SELL
$122.97 - $147.0 $103,540 - $123,774
-842 Reduced 1.91%
43,295 $5.63 Million
Q3 2020

Nov 13, 2020
SELL
$121.19 - $165.49 $1.29 Million - $1.76 Million
-10,610 Reduced 19.38%
44,137 $6.43 Million
Q2 2020

Aug 11, 2020
SELL
$104.21 - $156.44 $162,150 - $243,420
-1,556 Reduced 2.76%
54,747 $8.11 Million
Q1 2020

May 15, 2020
SELL
$93.12 - $133.99 $267,720 - $385,221
-2,875 Reduced 4.86%
56,303 $6.13 Million
Q4 2019

Feb 14, 2020
BUY
$74.51 - $124.23 $7,674 - $12,795
103 Added 0.17%
59,178 $6.82 Million
Q3 2019

Nov 14, 2019
SELL
$70.9 - $87.82 $227,801 - $282,165
-3,213 Reduced 5.16%
59,075 $4.75 Million
Q2 2019

Aug 14, 2019
BUY
$65.86 - $92.79 $277,599 - $391,109
4,215 Added 7.26%
62,288 $4.52 Million
Q1 2019

May 15, 2019
BUY
$72.76 - $93.45 $16,007 - $20,559
220 Added 0.38%
58,073 $5.43 Million
Q4 2018

Feb 15, 2019
BUY
$62.67 - $88.33 $27,449 - $38,688
438 Added 0.76%
57,853 $4.22 Million
Q3 2018

Nov 15, 2018
BUY
$87.52 - $122.67 $68,615 - $96,173
784 Added 1.38%
57,415 $5.03 Million
Q2 2018

Aug 14, 2018
BUY
$88.31 - $107.8 $1.21 Million - $1.48 Million
13,747 Added 32.06%
56,631 $5.58 Million
Q1 2018

May 11, 2018
BUY
$115.92 - $148.54 $226,971 - $290,841
1,958 Added 4.78%
42,884 $5.11 Million
Q4 2017

Feb 15, 2018
BUY
$114.49 - $139.98 $3.2 Million - $3.91 Million
27,914 Added 214.53%
40,926 $5.2 Million
Q3 2017

Nov 08, 2017
BUY
$72.53 - $118.27 $943,760 - $1.54 Million
13,012
13,012 $1.53 Million

Others Institutions Holding ALNY

# of Institutions
644
Shares Held
109M
Call Options Held
1.28M
Put Options Held
1.21M
View Full List

About ALNYLAM PHARMACEUTICALS, INC.

ALNY Quotes by TradingView
  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $31.2B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Macquarie Group LTD Portfolio

Follow Macquarie Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email